
Opinion|Videos|September 15, 2023
Available Treatment Options for Patients With Higher-Risk Myelofibrosis
Author(s)Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5


























